Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-09-28
2010-06-29
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S262000
Reexamination Certificate
active
07745450
ABSTRACT:
The invention relates to 3-, 5-, 7-trisubstituted pyrazolo[4,3-d]pyrimidines represented by the general formula Iand pharmaceutically acceptable salts thereof, whereinR3 is an optionally substituted alkyl, cycloalkyl, cycloheteroalkyl, cycloalkyl alkyl, aryl or alkylaryl group;R5 is halogen, —NHNH2, —NHOH, NHCONH2, guanylo (NH—C(NH)NH2) an optionally substituted C1-C6alkyl, alkenyl, alkynyl, C3-C15cycloalkyl, Rf(C3-C15cycloalkyl), heterocyclyl, heteroalkyl, aryl, heteroaryl, arylalkylene, arylalkenylene, arylalkynylene, cycloheteroalkyl, cycloheteroalkyl alkyl, heteroarylalkylene, heteroarylalkenylene, heteroarylalkynylene group, the group —C(O)—Ra, —C(O)NRbRc, —SO3Rd, or —NHC(O)Re, wherein Raand Rfare an optionally substituted C1-C6alkyl, alkenyl, or alkynyl group, Rb, Rc, and Rdare independently selected from the group consisting of H, optionally substituted C1-C6alkyl, alkenyl, or alkynyl group, and Reis a hydroxy, amino, alkoxy, alkylamino, optionally substituted C1-C6alkyl, alkenyl or alkynyl group; or the group —X—R5′, wherein X is —NH—, —O—, —S— or —N(alkyl)- and R5′ is hydrogen, an optionally substituted C1-C6alkyl, alkenyl, alkynyl, C3-C15cycloalkyl, Rf(C3-C15cycloalkyl), aryl, heterocyclyl, hetero C1-C6alkyl, arylalkylene, arylalkenylene, arylalkynylene, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkyl, or heteroarylalkylene, heteroarylalkenylene, heteroarylalkynylene group, the group —C(O)—Ra, —C(O)NRbRc, —SO3Rd, or —NHC(O)Re, wherein Ra, Rb, Rc, Rd, Reand Rfhave the above meaning, andR7 is halogen, —NHNH2, NHOH, NHCONH2, guanylo (NH—C(NH)NH2) or the group —X—R7′, wherein X has the above meaning and the meaning of R7′is as defined for R5′.
REFERENCES:
patent: 3988338 (1976-10-01), Skoog et al.
patent: 5723608 (1998-03-01), Yuan
patent: 6200980 (2001-03-01), Piazza et al.
patent: 2003/0195205 (2003-10-01), DeNinno et al.
patent: WO 98 29413 (1998-07-01), None
patent: WO 98 49166 (1998-11-01), None
patent: WO 99 54333 (1999-10-01), None
patent: WO 01 19827 (2001-03-01), None
Subramanyam et. al., J. Med. Chem., 1995, 38, 587-589.
Ellames et. al., J. Chem. Soc. Perkin. Trans., 1985, 1(10), 2087-2091.
Farkas et. al. Collect. Czech. Commun. 1972, 37(8), 2786-2797.
Long et. al. J. Heterocycl. Chem., 1970, 7(4), 863-869.
Hernandez et. al., J. Org. Chem., 1981, 46(20), 3941-3945.
Hecht et. al. (J. of Biol. Chem., 1975, 250(18), 7343-7351).
Subramanyam et al., “6-(4-Pyridinyl)-1H-1,2,3-triazolo [4, 5-d]-pyrimidine-4(5H)-one: A Structurally Novel Competitive AMPA Receptor Antagonist”J. Med. Chem., vol. 38, No. 4, pp. 587-589 (1995).
Buchanan et al., “C-nucleoside studies. Part 20538. Synthesis of some pyrazolo [4,3-d]pyrimidine acyclonucleosides related to (S)-(2,3-dihydroxypropyl)adenine; A direct method for double functionalization of the pyrazole ring”,J. Chem. Soc., Perkin Trans., vol. 1, No. 5, pp. 925-930, (1989).
Ellames et al., “The synthesis of acycloformycins and 5-amino-3-(2-hydroxyethoxy)methylpyrazolo [4,3-d]pyrimide in-7(6H)-one, an analog of the antiviral acycloguanosine”,J. Chem. Soc., Perkin Tans., vol. 1, No. 10, pp. 2087-2091, (1985).
Neuwels, “Approach to an adenosine pharmacophore by molecular modeling”,J. Pharm. Belg., vol. 47, No. 4, pp. 351-363, (1992).
Hecht, et al., Activation of cytokinins,J. Biol. Chem., vol. 250, No. 18, pp. 7343-7351, (1975).
Hernandez et al., A general route for the facile synthesis of 4-Thioxopyrimidin-2-one derivatives via the annulation of cyclic o-aminonitriles using carbonyl sulfide1,J. Org. Chem., vol. 46, No. 20, pp. 3941-3945, (1981).
Long et al., “Derivatives of the new ring system pyrazolo [4,3-d]-v-triazine and the synthesis of 5,7-disubstituted 3-methylpyrazolo [4,3-d]pyrimidines and 5,7-disubstituted 3-methylpyrazolo [4,3-d]pyrimidines 6-Oxides which are structurally related to the nucleoside antibiotics formycin and formycin B (1)”,J. Heterocycl. Chem., vol. 7, No. 4, pp. 863-869, (1970).
Farkas et al., Nucleic acid components and their analogs. CLI. The preparation of 1H-pyrazolo [4,3-d]pyrimidine as an approach to the synthesis of formycin BCollect. Czech. Chem. Commun., vol. 37, No. 8, pp. 2786-2797, (1972).
Sanghvi et al., In vivo antiviral activity of 5-amino-I-methyl-3-beta.-D-ribofuranosylpyrazolo [4,3-d]pyrimidin-7(6H)-one and related guanosine analogs prepared from formycin, vol. 10, No. 6, pp. 1417-1427, (1991).
Havlicek Libor
Krystof Vladimir
Lenobel René
Moravcová Daniela
Strnad Miroslav
Institute of Experimental Botany
Moore Susanna
Panitch Schwarze Belisario & Nadel LLP
Univerzita Palackeho v Olomouci
LandOfFree
Pyrazolo[4,3-d]pyrimidines, processes for their preparation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolo[4,3-d]pyrimidines, processes for their preparation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolo[4,3-d]pyrimidines, processes for their preparation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4176577